A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

PubWeight™: 10.90‹?› | Rank: Top 0.1%

🔗 View Article (PMID 32187464)

Published in N Engl J Med on March 18, 2020

Authors

Bin Cao1, Yeming Wang1, Danning Wen1, Wen Liu1, Jingli Wang1, Guohui Fan1, Lianguo Ruan1, Bin Song1, Yanping Cai1, Ming Wei1, Xingwang Li1, Jiaan Xia1, Nanshan Chen1, Jie Xiang1, Ting Yu1, Tao Bai1, Xuelei Xie1, Li Zhang1, Caihong Li1, Ye Yuan1, Hua Chen1, Huadong Li1, Hanping Huang1, Shengjing Tu1, Fengyun Gong1, Ying Liu1, Yuan Wei1, Chongya Dong1, Fei Zhou1, Xiaoying Gu1, Jiuyang Xu1, Zhibo Liu1, Yi Zhang1, Hui Li1, Lianhan Shang1, Ke Wang1, Kunxia Li1, Xia Zhou1, Xuan Dong1, Zhaohui Qu1, Sixia Lu1, Xujuan Hu1, Shunan Ruan1, Shanshan Luo1, Jing Wu1, Lu Peng1, Fang Cheng1, Lihong Pan1, Jun Zou1, Chunmin Jia1, Juan Wang1, Xia Liu1, Shuzhen Wang1, Xudong Wu1, Qin Ge1, Jing He1, Haiyan Zhan1, Fang Qiu1, Li Guo1, Chaolin Huang1, Thomas Jaki1, Frederick G Hayden1, Peter W Horby1, Dingyu Zhang1, Chen Wang1

Author Affiliations

1: From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).

Associated clinical trials:

Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) | NCT04320277

Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia (CCAP) | NCT04345289

Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19 | NCT04349592

Trial of Hydroxychloroquine In Covid-19 Kinetics (THICK) | NCT04353271

Passive Immunity Trial of Nashville II for COVID-19 (PassItOnII) | NCT04362176

Observational Cohort of COVID-19 Patients at Raymond-Poincare (COVID-RPC) | NCT04364698

C5a Receptor Expression - COVID-19 (C5-COV) (C5-COV) | NCT04369820

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 (TREATNOW) | NCT04372628

COVID-19 - Quality of Life After Infection | NCT04377464

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 | NCT04377503

Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19 | NCT04380870

Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure (CORMOR) | NCT04388514

Trial of Imatinib for Hospitalized Adults With COVID-19 | NCT04394416

Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) (PREVICHARM) | NCT04400019

The Açaí Berry COVID-19 Anti-Inflammation Trial (ACAI) | NCT04404218

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial (DART) | NCT04482621

Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19 | NCT04498936